Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 486

1.

Can BDDCS illuminate targets in drug design?

Bocci G, Benet LZ, Oprea TI.

Drug Discov Today. 2019 Oct 1. pii: S1359-6446(19)30381-2. doi: 10.1016/j.drudis.2019.09.021. [Epub ahead of print] Review.

PMID:
31585170
2.

Protein binding and hepatic clearance: Re-examining the discrimination between models of hepatic clearance with diazepam in the isolated perfused rat liver preparation.

Wang HJ, Benet LZ.

Drug Metab Dispos. 2019 Sep 28. pii: dmd.119.088872. doi: 10.1124/dmd.119.088872. [Epub ahead of print]

3.

In Vitro - In Vivo Accuracy: The CYP3A4 Anomaly.

Bowman CM, Benet LZ.

Drug Metab Dispos. 2019 Sep 24. pii: dmd.119.088427. doi: 10.1124/dmd.119.088427. [Epub ahead of print]

4.

Food, Acid Supplementation and Drug Absorption - a Complicated Gastric Mix: a Randomized Control Trial.

Surofchy DD, Frassetto LA, Benet LZ.

Pharm Res. 2019 Sep 4;36(11):155. doi: 10.1007/s11095-019-2693-5.

PMID:
31485804
5.

How Transporters Have Changed Basic Pharmacokinetic Understanding.

Benet LZ, Bowman CM, Sodhi JK.

AAPS J. 2019 Sep 3;21(6):103. doi: 10.1208/s12248-019-0373-3.

PMID:
31482335
6.

The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats.

Moriya Y, Kogame A, Tagawa Y, Morohashi A, Kondo T, Asahi S, Benet LZ.

Drug Metab Dispos. 2019 Sep;47(9):1004-1012. doi: 10.1124/dmd.119.087148. Epub 2019 Jun 14.

PMID:
31201213
7.

Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties.

Bowman CM, Benet LZ.

Pharm Res. 2019 May 31;36(8):113. doi: 10.1007/s11095-019-2645-0.

PMID:
31152241
8.

Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs.

Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK.

J Pharmacokinet Pharmacodyn. 2019 Apr;46(2):155-163. doi: 10.1007/s10928-019-09626-7. Epub 2019 Mar 25.

PMID:
30911879
9.

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.

Gandhi M, Bacchetti P, Rodrigues WC, Spinelli M, Koss CA, Drain PK, Baeten JM, Mugo NR, Ngure K, Benet LZ, Okochi H, Wang G, Vincent M.

EClinicalMedicine. 2018 Aug-Sep;2-3:22-28. doi: 10.1016/j.eclinm.2018.08.004. Epub 2018 Aug 31.

10.

In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction.

Bowman CM, Benet LZ.

J Pharm Sci. 2019 Jul;108(7):2500-2504. doi: 10.1016/j.xphs.2019.02.009. Epub 2019 Feb 25.

PMID:
30817922
11.

Characterization of Fasiglifam-Related Liver Toxicity in Dogs.

Kogame A, Moriya Y, Mori I, Pan L, Morohashi A, Ebihara T, Fukui H, Tagawa Y, Benet LZ.

Drug Metab Dispos. 2019 May;47(5):525-534. doi: 10.1124/dmd.118.084889. Epub 2019 Feb 14.

PMID:
30765394
12.

The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation.

Bowman CM, Okochi H, Benet LZ.

Drug Metab Dispos. 2019 Apr;47(4):358-363. doi: 10.1124/dmd.118.085779. Epub 2019 Jan 23.

PMID:
30674616
13.

Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?

Benet LZ, Jayachandran P, Carroll KJ, Burmeister Getz E.

Clin Pharmacol Ther. 2019 Feb;105(2):326-328. doi: 10.1002/cpt.1294. Epub 2019 Jan 16. No abstract available.

PMID:
30652313
14.

Evaluating Within-Subject Variability for Narrow Therapeutic Index Drugs.

Jayachandran P, Okochi H, Frassetto LA, Park W, Fang L, Zhao L, Benet LZ.

Clin Pharmacol Ther. 2019 Feb;105(2):411-416. doi: 10.1002/cpt.1293. Epub 2019 Jan 16.

PMID:
30652304
15.

TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling.

Wolfe AR, Neitz RJ, Burlingame M, Suzuki BM, Lim KC, Scheideler M, Nelson DL, Benet LZ, Caffrey CR.

Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):571-586. doi: 10.1016/j.ijpddr.2018.10.004. Epub 2018 Nov 20.

16.

Ascorbic acid metabolites are involved in intraocular pressure control in the general population.

Hysi PG, Khawaja AP, Menni C, Tamraz B, Wareham N, Khaw KT, Foster PJ, Benet LZ, Spector TD, Hammond CJ.

Redox Biol. 2019 Jan;20:349-353. doi: 10.1016/j.redox.2018.10.004. Epub 2018 Oct 13.

17.

The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses.

Benet LZ, Bowman CM, Liu S, Sodhi JK.

Pharm Res. 2018 Oct 22;35(12):242. doi: 10.1007/s11095-018-2524-0.

18.

An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation.

Bowman CM, Benet LZ.

Eur J Pharm Sci. 2018 Oct 15;123:502-514. doi: 10.1016/j.ejps.2018.08.008. Epub 2018 Aug 8. Review.

19.

Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification.

Chan R, Benet LZ.

Toxicol Res (Camb). 2018 May 8;7(3):358-370. doi: 10.1039/C8TX00016F. Epub 2018 Apr 18.

20.

Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype.

Benet LZ.

J Clin Pharmacol. 2018 Apr 17. doi: 10.1002/jcph.1105. [Epub ahead of print] Review.

PMID:
29663413
21.

Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

Parasrampuria DA, Benet LZ, Sharma A.

AAPS J. 2018 Mar 13;20(3):46. doi: 10.1208/s12248-018-0204-y.

PMID:
29536211
22.

Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Phung N, Kuncze K, Okochi H, Louie A, Benet LZ, Ofokotun I, Haas DW, Currier JS, Chawana TD, Sheth AN, Bacchetti P, Gandhi M, Horng H.

Rapid Commun Mass Spectrom. 2018 Mar 15;32(5):431-441. doi: 10.1002/rcm.8058.

23.

Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.

Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN.

Sci Rep. 2018 Jan 8;8(1):92. doi: 10.1038/s41598-017-18436-1.

24.

Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.

Chan R, Benet LZ.

Toxicol Sci. 2018 Apr 1;162(2):499-508. doi: 10.1093/toxsci/kfx284.

25.

Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M.

Clin Infect Dis. 2018 Jan 6;66(2):213-219. doi: 10.1093/cid/cix755.

26.

The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio.

Benet LZ, Liu S, Wolfe AR.

Clin Pharmacol Ther. 2018 Mar;103(3):521-525. doi: 10.1002/cpt.802. Epub 2017 Sep 6.

27.

Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide".

Morrissey KM, Benet LZ, Ware JA.

Clin Transl Sci. 2017 Jul;10(4):240-241. doi: 10.1111/cts.12476. Epub 2017 Jun 29. No abstract available.

28.

Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics.

Benet LZ, Wu HF.

J Pharm Sci. 2017 Sep;106(9):2231-2233. doi: 10.1016/j.xphs.2017.05.008. Epub 2017 May 11.

PMID:
28502797
29.

Cellular Uptake of Levocetirizine by Organic Anion Transporter 4.

Noguchi S, Nishimura T, Mukaida S, Benet LZ, Nakashima E, Tomi M.

J Pharm Sci. 2017 Sep;106(9):2895-2898. doi: 10.1016/j.xphs.2017.03.026. Epub 2017 Apr 4.

PMID:
28385546
30.

Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.

Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ.

J Pharm Sci. 2017 Sep;106(9):2751-2757. doi: 10.1016/j.xphs.2017.03.027. Epub 2017 Apr 3.

31.

Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS).

Li J, Larregieu CA, Benet LZ.

Chin J Nat Med. 2016 Dec;14(12):888-897. doi: 10.1016/S1875-5364(17)30013-4. Review.

PMID:
28262115
32.

Evaluation of DILI Predictive Hypotheses in Early Drug Development.

Chan R, Benet LZ.

Chem Res Toxicol. 2017 Apr 17;30(4):1017-1029. doi: 10.1021/acs.chemrestox.7b00025. Epub 2017 Mar 15.

33.

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.

Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):778-783. doi: 10.1089/aid.2016.0202. Epub 2017 Mar 2.

34.

Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.

Faber KP, Wu HF, Yago MR, Xu X, Kadiyala P, Frassetto LA, Benet LZ.

Pharm Res. 2017 Mar;34(3):619-628. doi: 10.1007/s11095-016-2090-2. Epub 2016 Dec 27.

PMID:
28028768
35.

Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM.

Lancet HIV. 2016 Nov;3(11):e521-e528. doi: 10.1016/S2352-3018(16)30153-9. Epub 2016 Aug 31.

36.

Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.

Burmeister Getz E, Carroll KJ, Mielke J, Benet LZ, Jones B.

Clin Pharmacol Ther. 2017 Mar;101(3):331-340. doi: 10.1002/cpt.535. Epub 2016 Nov 26.

37.

Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System.

Bowman CM, Benet LZ.

Drug Metab Dispos. 2016 Nov;44(11):1731-1735. Epub 2016 Aug 12.

PMID:
27519549
38.

2016 Remington Honor Medal Address: Science for the profession.

Benet LZ.

J Am Pharm Assoc (2003). 2016 Jul-Aug;56(4):365-8. doi: 10.1016/j.japh.2016.06.008. No abstract available.

PMID:
27450136
39.

BDDCS, the Rule of 5 and drugability.

Benet LZ, Hosey CM, Ursu O, Oprea TI.

Adv Drug Deliv Rev. 2016 Jun 1;101:89-98. doi: 10.1016/j.addr.2016.05.007. Epub 2016 May 13. Review.

40.

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.

Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M.

Int J Tuberc Lung Dis. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882.

41.

Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial.

Burmeister Getz E, Carroll KJ, Jones B, Benet LZ.

Clin Pharmacol Ther. 2016 Sep;100(3):223-31. doi: 10.1002/cpt.373. Epub 2016 Apr 28.

43.

BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Hosey CM, Chan R, Benet LZ.

AAPS J. 2016 Jan;18(1):251-60. doi: 10.1208/s12248-015-9845-2. Epub 2015 Nov 20. Review.

45.

Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Zheng Y, Chen X, Benet LZ.

Clin Pharmacokinet. 2016 Feb;55(2):143-67. doi: 10.1007/s40262-015-0310-2. Review.

46.

Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.

Garrison KL, Sahin S, Benet LZ.

J Pharm Sci. 2015 Sep;104(9):3229-35. doi: 10.1002/jps.24505. Epub 2015 May 25.

47.

Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.

Hosey CM, Benet LZ.

Mol Pharm. 2015 May 4;12(5):1456-66. doi: 10.1021/mp500783g. Epub 2015 Apr 23.

48.

A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.

Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG 3rd.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):377-83. doi: 10.1016/j.clml.2015.02.016. Epub 2015 Feb 14.

PMID:
25776193
49.

pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion.

Zheng Y, Benet LZ, Okochi H, Chen X.

Pharm Res. 2015 Aug;32(8):2516-26. doi: 10.1007/s11095-015-1640-3. Epub 2015 Feb 19.

50.

Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful.

Parasrampuria DA, Benet LZ.

Basic Clin Pharmacol Toxicol. 2015 Jul;117(1):44-51. doi: 10.1111/bcpt.12352. Epub 2014 Dec 23. Review.

Supplemental Content

Loading ...
Support Center